Hemorrhagic cystitis

Summary

Hemorrhagic cystitis (MONDO:0000496) is a disease and 9 clinical trials. Top therapeutic interventions include posoleucel and chlorophyllin copper complex. A subtype of cystitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 9

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	hemorrhagic cystitis
Mondo ID	MONDO:0000496
DOID	DOID:0050859
NCIT	C114666
SNOMED CT	87696004
UMLS	C0085692
MedGen	508360
Is cancer (heuristic)	no

Disease family

This is a subtype of cystitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › urinary system disorder › urinary bladder disorder › cystitis › hemorrhagic cystitis

Related subtypes (13): prostatocystitis, acute cystitis, diphtheritic cystitis, trigonitis, radiation cystitis, cystitis cystica, emphysematous cholecystitis, chronic cystitis, acalculous cholecystitis, gonococcal cystitis, pyelocystitis, eosinophilic cryptitis, Trichomonas cystitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 9.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	3
Not specified	3
PHASE3	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05726786	PHASE3	RECRUITING	The Role of Preoperative Immunonutrition on Morbidity and Immune Response After Cystectomy (INCyst Trial)
NCT04390113	PHASE3	TERMINATED	Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC)
NCT02172963	PHASE1/PHASE2	COMPLETED	A Pilot Study Using Placenta Derived Decidual Stromal Cells for Hemorrhagic Cystitis
NCT02174536	PHASE2	UNKNOWN	A Double Blind Randomized Study Using Placenta Derived Decidual Stromal Cells for Hemorrhagic Cystitis
NCT03129126	PHASE2	COMPLETED	The Safety, Tolerability and Efficacy of LP-10 in Subjects With Refractory Moderate to Severe Hemorrhagic Cystitis
NCT05348239	PHASE2	UNKNOWN	Chlorophyllin Tablets for Urinary Bleeding Following Radiation Therapy for Cancers of Pelvic Organs
NCT06198517	Not specified	RECRUITING	Moxibustion for the Prevention of Hemorrhagic Cystitis After Allo-HSCT
NCT06241274	Not specified	RECRUITING	Moxibustion in the Treatment of Hemorrhagic Cystitis After Allo-HSCT
NCT04696666	Not specified	UNKNOWN	Tolerability and Efficacy of INSTYLAN in Subjects With Moderate to Severe Hemorrhagic Cystitis

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
POSOLEUCEL	3	1
CHLOROPHYLLIN COPPER COMPLEX	2	1